Welcome to our dedicated page for Core Laboratories /DE/ SEC filings (Ticker: CLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Core Laboratories /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Core Laboratories /DE/'s regulatory disclosures and financial reporting.
Core Laboratories Inc. (CLB) reports that director Kwaku Temeng has resigned from the Board of Directors, effective October 1, 2026. He currently serves as Chairman of the Nominating Committee and as a member of the Compensation Committee.
Temeng informed the Board verbally on August 19, 2026 and confirmed by letter on August 25, 2026. His letter states that the resignation is due to a disagreement with the Board regarding the Company’s strategic direction and certain governance practices. The Board believes his primary disagreement involves how succession planning is being conducted and concerns about the Company’s research priorities. His resignation letter is included as an exhibit, and the Company notes his more than five years of service and contributions.
Disciplined Growth Investors, Inc. reported its beneficial ownership of common shares of Core Laboratories Inc. as of 06/30/2026. The firm beneficially owns 3,042,177 common shares, representing 6.6% of the class. It has sole voting power over 2,961,959 shares and sole dispositive power over all 3,042,177 shares, with no shared voting or dispositive power indicated. This reflects a significant institutional stake held and controlled solely by Disciplined Growth Investors, Inc.
Ariel Investments, LLC reports significant ownership in Core Laboratories Inc common stock. Ariel beneficially owns 14,074,945 shares, representing 30.5% of the outstanding common stock as of June 30, 2026. Ariel has sole voting power over 13,141,081 shares and sole dispositive power over 14,074,945 shares, with no shared voting or dispositive power.
Ariel’s advisory clients are entitled to receive dividends and sale proceeds for all securities reported. Ariel Fund, a series of Ariel Investment Trust, owns 6,474,663 shares of Core Laboratories, which represents an economic interest in more than 5% of the class.
BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership of common stock of Core Laboratories Inc. BlackRock reports beneficial ownership of 3,811,390 shares, representing 8.3% of the common stock. It has sole voting power over 3,703,577 shares and sole dispositive power over 3,811,390 shares, with no shared voting or dispositive power reported. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Core Laboratories’ outstanding common shares.
Core Laboratories Inc. reported that Chairman and CEO Bruno Lawrence purchased 5,000 shares of common stock on July 31, 2026 at $10.78 per share, described as a purchase in open market or private transaction. After this trade, his directly held stake totaled 262,438 shares.
Core Laboratories CAO & Treasurer Teo Sow Hang exercised 440 Restricted Shares into Common Stock on August 1, 2026, and disposed of 198 Common shares at $10.64 per share to pay the exercise price or tax liability. The Restricted Shares vest annually over six years and reflect multiple grants.
Core Laboratories executive Mark Damian Tattoli exercised restricted share awards for 250 underlying common shares at $0 on 1 August 2026. The related restricted shares were canceled and 99 common shares were disposed of at $10.64 per share as payment of exercise price or tax liability. Following these transactions he holds 950 restricted shares directly, plus indirect common stock positions of 20 shares in a custodial account and 1,694.8420 shares in a 401 (k) Plan. These transactions were not reported under a Rule 10b5-1 trading plan.
Core Laboratories Inc. generated revenue of $124,609 thousand for the quarter ended June 30, 2026, down 4% from the prior-year period. Services contributed $94,277 thousand and product sales $30,332 thousand. Operating income declined to $9,151 thousand, and net income attributable to the company fell to $5,956 thousand, or diluted EPS of $0.13.
For the first six months of 2026, revenue was $246,406 thousand and net income attributable to Core Laboratories was $5,167 thousand. Net cash provided by operating activities totaled $11,774 thousand, while capital expenditures were $10,659 thousand. Long-term debt stood at $116,375 thousand with a leverage ratio of 1.30 and interest coverage of 6.53; the current ratio was 2.12:1, and available borrowing capacity under the credit facility was approximately $85.6 million.
Management highlights ongoing geopolitical conflicts in the Middle East and Russia–Ukraine region, noting a 15% to 20% reduction in global cargo movement of crude oil and derived products in the second quarter of 2026 versus a year earlier, which is reducing demand for certain laboratory assay services, though large international projects are described as more resilient.
Core Laboratories Inc. reported second‑quarter 2026 revenue of $124,609,000, up 2.3% sequentially and down 4.3% year‑over‑year. GAAP operating income was $9,151,000 and diluted EPS attributable to Core was $0.13, while EPS excluding specified items was $0.11. Reservoir Description revenue was $78,747,000 with 5% operating margin, pressured by Middle East and Russia‑Ukraine disruptions, while Production Enhancement revenue was $45,862,000 with 12% operating margin and 15% sequential growth.
Core generated free cash flow of $3,122,000 on net cash from operations of $7,809,000 and $4,687,000 of operational capital expenditures. It repurchased 214,712 shares for approximately $2,700,000 and ended June 30, 2026 with net debt of $93,600,000 and a leverage ratio of 1.30. The Board declared a quarterly dividend of $0.01 per share payable August 31, 2026.
Management projects third‑quarter 2026 revenue of $128,500,000–$135,500,000, operating income of $10,500,000–$15,000,000 and EPS of $0.12–$0.20, assuming a 25% tax rate. Return on invested capital for the last four quarters was 8.3%, reflecting the company’s asset‑light model and emphasis on proprietary technologies and international growth despite geopolitical headwinds.
Core Laboratories Inc. ownership disclosure: Disciplined Growth Investors, Inc. reports beneficial ownership of 4,937,115 common shares of Core Laboratories Inc., representing 10.7% of the class. The filer reports sole voting power over 4,653,638 shares and sole dispositive power over 4,937,115 shares. The filing is signed by Peter G. Rieke on 05/15/2026.